Medical Oncology Department, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Sarcoma Patient Advocacy Global Network (SPAGN), Untergasse 36, D-61200, Wölfersheim, Germany.
BMC Cancer. 2024 Aug 6;24(1):962. doi: 10.1186/s12885-024-12732-6.
Typically, researchers and clinicians determine the agenda in sarcoma research. However, patient involvement can have a meaningful impact on research. Therefore, the Patient-Powered Research Network (PPRN) of the Sarcoma Patient Advocacy Global Network (SPAGN) set up a Priority Setting Partnership (PSP). The primary objective of this partnership is to identify priorities for research and patient advocacy topics.
In the first phase of this PSP, including 264 sarcoma patients and carers from all over the world, 23 research topics regarding sarcomas and 15 patient advocacy topics were identified using an online survey. In the second phase, participants were asked to fill in a top five and a top three of research and patient advocacy topics, respectively. Additionally, sociodemographic characteristics and sarcoma characteristics were collected. Social media channels, local national patient advocacy groups and the SPAGN website were used to distribute the survey.
In total, 671 patients (75%) and carers (25%) participated in this survey. The five highest ranked research topics were related to causes of sarcoma (43%), prognosis and risk of recurrence (40%), specific subtypes of sarcoma (33%), the role of immunotherapy, targeted therapy and combined therapy (30%), and hereditary aspects (30%). The three highest ranked patient advocacy topics were improving the diagnostic process of sarcoma (39%), access to tumor DNA analysis (37%) and establishing an international sarcoma registry (37%).
This sarcoma PSP has identified priorities for research and patient advocacy, offering guidance for researchers, assisting funding agencies with assessing project relevance and empowering patient advocates to represent the needs of patients and carers.
通常情况下,肉瘤研究的议程由研究人员和临床医生决定。然而,患者的参与可能会对研究产生有意义的影响。因此,肉瘤患者倡导全球网络(SPAGN)的患者驱动研究网络(PPRN)成立了一个优先事项设定伙伴关系(PSP)。该伙伴关系的主要目标是确定研究和患者倡导主题的优先事项。
在该 PSP 的第一阶段,包括来自世界各地的 264 名肉瘤患者和护理人员,使用在线调查确定了 23 个肉瘤研究主题和 15 个患者倡导主题。在第二阶段,要求参与者分别填写研究和患者倡导主题的前五名和前三名。此外,还收集了社会人口统计学特征和肉瘤特征。通过社交媒体渠道、当地国家患者倡导团体和 SPAGN 网站分发了调查。
共有 671 名患者(75%)和护理人员(25%)参与了这项调查。排名前五的研究主题与肉瘤的病因(43%)、预后和复发风险(40%)、特定亚型肉瘤(33%)、免疫疗法、靶向疗法和联合疗法的作用(30%)以及遗传方面(30%)有关。排名前三的患者倡导主题是改善肉瘤的诊断过程(39%)、获得肿瘤 DNA 分析(37%)和建立国际肉瘤登记处(37%)。
该肉瘤 PSP 确定了研究和患者倡导的优先事项,为研究人员提供了指导,帮助资助机构评估项目相关性,并使患者倡导者有能力代表患者和护理人员的需求。